- call +1-201-465-4211
- email sales@mrinsights.biz
When infection attacks the body, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic; including antitubercular), antiviral, antifungal and antiparasitic (including antiprotozoal and antihelminthic) agents.
Scope of the Report:
This report studies the Infectious Diseases market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Infectious Diseases market by product type and applications/end industries.
Depending on the severity and the type of infection, the antibiotic may be given by mouth or by injection, or may be applied topically. Severe infections of the brain are usually treated with intravenous antibiotics. Sometimes, multiple antibiotics are used in case there is resistance to one antibiotic.
The global Infectious Diseases market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Infectious Diseases.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Astellas Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Chimerix Pharmaceuticals
Cubist
Eli Lilly
Isis Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Sanofi
Vertex
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Antibacterial drugs
Antiviral drugs
Antifungal drugs
Antiparasitic drugs
Market Segment by Applications, can be divided into
Acquired Immune Deficiency Syndrome
Hepatitis B
Hepatitis C
Human Papillomavirus
Hospital acquired Methicillin-resistant Staphylococcus aureus infection
Chlamydia trachomatis and Neisseria Gonorrhea
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Infectious Diseases Market Overview
1.1 Product Overview and Scope of Infectious Diseases
1.2 Classification of Infectious Diseases by Types
1.2.1 Global Infectious Diseases Revenue Comparison by Types (2017-2023)
1.2.2 Global Infectious Diseases Revenue Market Share by Types in 2017
1.2.3 Antibacterial drugs
1.2.4 Antiviral drugs
1.2.5 Antifungal drugs
1.2.6 Antiparasitic drugs
1.3 Global Infectious Diseases Market by Application
1.3.1 Global Infectious Diseases Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Acquired Immune Deficiency Syndrome
1.3.3 Hepatitis B
1.3.4 Hepatitis C
1.3.5 Human Papillomavirus
1.3.6 Hospital acquired Methicillin-resistant Staphylococcus aureus infection
1.3.7 Chlamydia trachomatis and Neisseria Gonorrhea
1.4 Global Infectious Diseases Market by Regions
1.4.1 Global Infectious Diseases Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Infectious Diseases Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Infectious Diseases Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Infectious Diseases Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Infectious Diseases Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Infectious Diseases Status and Prospect (2013-2023)
1.5 Global Market Size of Infectious Diseases (2013-2023)
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche
2.1.1 Business Overview
2.1.2 Infectious Diseases Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F. Hoffmann-La Roche Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.2 Gilead Sciences
2.2.1 Business Overview
2.2.2 Infectious Diseases Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Gilead Sciences Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 Infectious Diseases Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Infectious Diseases Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merck
2.5.1 Business Overview
2.5.2 Infectious Diseases Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Merck Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Infectious Diseases Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.7 AbbVie
2.7.1 Business Overview
2.7.2 Infectious Diseases Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AbbVie Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.8 Astellas Pharma
2.8.1 Business Overview
2.8.2 Infectious Diseases Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Astellas Pharma Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.9 AstraZeneca
2.9.1 Business Overview
2.9.2 Infectious Diseases Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 AstraZeneca Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.10 Bayer
2.10.1 Business Overview
2.10.2 Infectious Diseases Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Bayer Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.11 Bristol-Myers Squibb
2.11.1 Business Overview
2.11.2 Infectious Diseases Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bristol-Myers Squibb Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.12 Chimerix Pharmaceuticals
2.12.1 Business Overview
2.12.2 Infectious Diseases Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Chimerix Pharmaceuticals Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.13 Cubist
2.13.1 Business Overview
2.13.2 Infectious Diseases Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Cubist Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.14 Eli Lilly
2.14.1 Business Overview
2.14.2 Infectious Diseases Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Eli Lilly Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.15 Isis Pharmaceuticals
2.15.1 Business Overview
2.15.2 Infectious Diseases Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Isis Pharmaceuticals Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.16 Mitsubishi Tanabe Pharma
2.16.1 Business Overview
2.16.2 Infectious Diseases Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Mitsubishi Tanabe Pharma Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.17 Novartis
2.17.1 Business Overview
2.17.2 Infectious Diseases Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Novartis Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.18 Sanofi
2.18.1 Business Overview
2.18.2 Infectious Diseases Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Sanofi Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.19 Vertex
2.19.1 Business Overview
2.19.2 Infectious Diseases Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Vertex Infectious Diseases Revenue, Gross Margin and Market Share (2016-2017)
3 Global Infectious Diseases Market Competition, by Players
3.1 Global Infectious Diseases Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Infectious Diseases Players Market Share
3.2.2 Top 10 Infectious Diseases Players Market Share
3.3 Market Competition Trend
4 Global Infectious Diseases Market Size by Regions
4.1 Global Infectious Diseases Revenue and Market Share by Regions
4.2 North America Infectious Diseases Revenue and Growth Rate (2013-2018)
4.3 Europe Infectious Diseases Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Infectious Diseases Revenue and Growth Rate (2013-2018)
4.5 South America Infectious Diseases Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Infectious Diseases Revenue and Growth Rate (2013-2018)
5 North America Infectious Diseases Revenue by Countries
5.1 North America Infectious Diseases Revenue by Countries (2013-2018)
5.2 USA Infectious Diseases Revenue and Growth Rate (2013-2018)
5.3 Canada Infectious Diseases Revenue and Growth Rate (2013-2018)
5.4 Mexico Infectious Diseases Revenue and Growth Rate (2013-2018)
6 Europe Infectious Diseases Revenue by Countries
6.1 Europe Infectious Diseases Revenue by Countries (2013-2018)
6.2 Germany Infectious Diseases Revenue and Growth Rate (2013-2018)
6.3 UK Infectious Diseases Revenue and Growth Rate (2013-2018)
6.4 France Infectious Diseases Revenue and Growth Rate (2013-2018)
6.5 Russia Infectious Diseases Revenue and Growth Rate (2013-2018)
6.6 Italy Infectious Diseases Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Infectious Diseases Revenue by Countries
7.1 Asia-Pacific Infectious Diseases Revenue by Countries (2013-2018)
7.2 China Infectious Diseases Revenue and Growth Rate (2013-2018)
7.3 Japan Infectious Diseases Revenue and Growth Rate (2013-2018)
7.4 Korea Infectious Diseases Revenue and Growth Rate (2013-2018)
7.5 India Infectious Diseases Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Infectious Diseases Revenue and Growth Rate (2013-2018)
8 South America Infectious Diseases Revenue by Countries
8.1 South America Infectious Diseases Revenue by Countries (2013-2018)
8.2 Brazil Infectious Diseases Revenue and Growth Rate (2013-2018)
8.3 Argentina Infectious Diseases Revenue and Growth Rate (2013-2018)
8.4 Colombia Infectious Diseases Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Infectious Diseases by Countries
9.1 Middle East and Africa Infectious Diseases Revenue by Countries (2013-2018)
9.2 Saudi Arabia Infectious Diseases Revenue and Growth Rate (2013-2018)
9.3 UAE Infectious Diseases Revenue and Growth Rate (2013-2018)
9.4 Egypt Infectious Diseases Revenue and Growth Rate (2013-2018)
9.5 Nigeria Infectious Diseases Revenue and Growth Rate (2013-2018)
9.6 South Africa Infectious Diseases Revenue and Growth Rate (2013-2018)
10 Global Infectious Diseases Market Segment by Type
10.1 Global Infectious Diseases Revenue and Market Share by Type (2013-2018)
10.2 Global Infectious Diseases Market Forecast by Type (2018-2023)
10.3 Antibacterial drugs Revenue Growth Rate (2013-2023)
10.4 Antiviral drugs Revenue Growth Rate (2013-2023)
10.5 Antifungal drugs Revenue Growth Rate (2013-2023)
10.6 Antiparasitic drugs Revenue Growth Rate (2013-2023)
11 Global Infectious Diseases Market Segment by Application
11.1 Global Infectious Diseases Revenue Market Share by Application (2013-2018)
11.2 Infectious Diseases Market Forecast by Application (2018-2023)
11.3 Acquired Immune Deficiency Syndrome Revenue Growth (2013-2018)
11.4 Hepatitis B Revenue Growth (2013-2018)
11.5 Hepatitis C Revenue Growth (2013-2018)
11.6 Human Papillomavirus Revenue Growth (2013-2018)
11.7 Hospital acquired Methicillin-resistant Staphylococcus aureus infection Revenue Growth (2013-2018)
11.8 Chlamydia trachomatis and Neisseria Gonorrhea Revenue Growth (2013-2018)
12 Global Infectious Diseases Market Size Forecast (2018-2023)
12.1 Global Infectious Diseases Market Size Forecast (2018-2023)
12.2 Global Infectious Diseases Market Forecast by Regions (2018-2023)
12.3 North America Infectious Diseases Revenue Market Forecast (2018-2023)
12.4 Europe Infectious Diseases Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Infectious Diseases Revenue Market Forecast (2018-2023)
12.6 South America Infectious Diseases Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Infectious Diseases Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Infectious Diseases Picture
Table Product Specifications of Infectious Diseases
Table Global Infectious Diseases and Revenue (Million USD) Market Split by Product Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
